<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127892">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02084875</url>
  </required_header>
  <id_info>
    <org_study_id>A3921180</org_study_id>
    <nct_id>NCT02084875</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Open Label, Single Dose, 2-Period Crossover Study To Evaluate The Effect Of Food On The Pharmacokinetics Of Tofacitinib Modified Release (MR) 11 Mg Tablets In Healthy Western And Japanese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the drug behavior and safety of a single dose of the 11 milligram
      tofacitinib (CP-690,550) modified-release formulation in 24 healthy volunteers when taken
      after eating a high fat meal (the effect of food). This will be compared to the drug
      behavior and safety of a single dose of the 11 milligram tofacitinib (CP-690,550)
      modified-release formulation when taken after a 10 hour fast.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Area under the curve from time zero to infinity</measure>
    <time_frame>48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the curve from time zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration</measure>
    <time_frame>48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration-time profile from time zero to time of the last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum Observed Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to peak concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>48 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>tofacitinib MR 11 mg Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tofacitinib modified release (MR) 11 mg tablet administered with food.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tofacitinib MR 11 mg Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tofacitinib modified release (MR) 11 mg tablet administered without food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tofacitinib modified-release (MR) formulation</intervention_name>
    <description>A single dose of tofacitinib modified release 11 mg tablet after receiving the standard FDA high fat/high calorie meal.</description>
    <arm_group_label>tofacitinib MR 11 mg Fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tofacitinib modified-release (MR) formulation</intervention_name>
    <description>tofacitinib modified release (MR) 11 mg tablet after a 10 hour overnight fast.</description>
    <arm_group_label>tofacitinib MR 11 mg Fasting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers and/or healthy females volunteers of non-childbearing
             potential who are 18 to 55 years of age;

          -  Healthy volunteers who are of Japanese or Western descent;

          -  Healthy volunteers with no evidence of active or latent or inadequately treated
             tuberculosis.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease;

          -  Clinically significant infections within the past 3 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921180&amp;StudyName=A%20Study%20To%20Evaluate%20The%20Effect%20Of%20Food%20On%20The%20Behavior%20Of%20Tofacitinib%20Modified%20Release%2011%20Milligram%20Tablets%20In%20Healthy%20Western%20And%2</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>March 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Food effect</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>healthy volunteer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
